China Pharma Holdings (CPHI) Long-Term Deferred Tax (2011 - 2026)

China Pharma Holdings (CPHI) has reported Long-Term Deferred Tax for 15 consecutive years, with $22.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Deferred Tax rose 1.81% year-over-year to $22.5 million; the trailing twelve-month figure through Jun 2026 stood at $22.5 million (up 1.81% YoY), and the FY2025 full-year result was $21.2 million, down 2.3% from the prior year.
• Long-Term Deferred Tax advanced to $22.5 million in Q2 2026 per CPHI's latest filing, from $21.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $23.8 million in Q1 2022 and bottomed at $20.0 million in Q2 2023.
• Historically, Long-Term Deferred Tax has averaged $22.0 million across 5 years, with a median of $22.0 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax slumped 43.81% in 2022, then increased 1.81% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $22.0 million in 2022, then retreated by 2.07% to $21.5 million in 2023, then rose by 0.78% to $21.7 million in 2024, then declined by 2.3% to $21.2 million in 2025, then climbed by 6.13% to $22.5 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $22.5 million, $21.8 million, and $21.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.